• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma, Inc. - Common Stock (NQ:SILO)

    0.3850 -0.0102 (-2.58%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Silo Pharma, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
    Via Chartmill
    News headline image
    Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
    Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategy 
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security ↗
    Silo Pharma partners with Fireblocks to secure its crypto treasury platform using multi-layer enterprise security and governance standards. 
    Via Benzinga
    News headline image
    These stocks are moving in today's pre-market session ↗
    The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
    Via Chartmill
    News headline image
    Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    3 Under-the-Radar Biotechs Under $5 That Could Soar 200% ↗
    3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX. 
    Via MarketBeat
    News headline image
    Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers ↗
    Hoth Therapeutics reported strong preclinical efficacy and safety data for HT-KIT, a precision antisense therapy targeting KIT-driven cancers. 
    Via Benzinga
    News headline image
    Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days
    Via Investor Brand Network
    News headline image
    Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
    Via Get News
    Topics Intellectual Property
    News headline image
    Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
    Via Press Release Distribution Service
    Topics Intellectual Property
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives USPTO Notice of Allowance for PTSD Treatment Patent
    Via Investor Brand Network
    Topics Intellectual Property
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.